Sec­tion 8. Obe­si­ty and Weight Man­age­ment for the Pre­ven­tion and Treat­ment of Type 2 Di­a­betes

(https:/​/​doi.org/​10.2337/​dc23-​S008)

Lan­guage was amend­ed to re­in­force that obe­si­ty is a chron­ic dis­ease.

Rec­om­men­da­tion 8.5 was added to re­in­force that both small and larg­er weight loss­es should be con­sid­ered as treat­ment goals on a case-​by-​case ba­sis. No­tably, larg­er (10% or more) weight loss may have dis­ease-​mod­i­fy­ing ef­fects, in­clud­ing di­a­betes re­mis­sion, and may im­prove long-​term car­dio­vas­cu­lar out­comes.

Dual GLP-​1/​glu­cose-​de­pen­dent in­sulinotrop­ic polypep­tide (GIP) re­cep­tor ag­o­nist (tirzepatide) was added as a glu­coselow­er­ing op­tion with the po­ten­tial for weight loss.